StockData
Panacea Life Sciences Holdings, Inc. logo

Panacea Life Sciences Holdings, Inc. (PLSH) stock

PLSHOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Số liệu tài chính tới Q1 năm tài chính 2024, quý kết thúc ngày Mar 31, 2024Last filing: 10-Q on May 6, 2024
$0.07+0.00 (+5.45%)

Close on Oct 19, 2026Market cap $1.15MP/E –Yield –

Panacea Life Sciences Holdings, Inc. grew revenue 50.4% to $2.76M over the twelve months to Mar 31, 2024. Free cash flow was -$1.59M. At the latest close the market valued the company at $1.15M.

Revenue
$2.76M
+50.4% vs. a year earlier
Operating income
-$5.31M
TTM Q1 2024
Free cash flow
-$1.59M
FY2023
EPS, diluted
-$0.46
TTM Q1 2024

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2024

Valuation

Market cap
$1.15M
P/E ratio
–
Price to sales
0.42
Price to book
–
Dividend yield
–
Free cash flow yield
-138.50%

Fundamentals

Revenue
$2.76M
Net income
-$7.67M
EPS, diluted
-$0.46
Free cash flow
-$1.59M
Book value per share
-$0.58
Diluted shares
16M

Trading

Previous close
$0.07
Open
$0.07
Day's range
$0.07 – $0.07
Volume
2,000
Average volume (20 days)
3,817

Market cap history

Month-end market cap since 2022, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodPLSHS&P 500DifferencePLSH per yearS&P 500 per year
1 month-4.0%+0.6%−4.6 pts
3 months-7.2%+3.4%−10.6 pts
Year to date+39.2%+13.3%+25.9 pts
1 year-0.6%+16.6%−17.2 pts
3 years-75.1%+86.4%−161.5 pts-37.1%+23.1%

Eleven years at a glance

Fiscal years 2013 to 2023 and trailing twelve months, USD

Revenue

$2.76M+50.4% YoY

Gross profit

$1.56M+199.5% YoY

Operating income

-$5.31M

Net income

-$7.67M

EPS, diluted

-$0.46

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Panacea Life Sciences filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Panacea Life Sciences

Medicinal Chemicals & Botanical Products

Panacea Life Sciences Holdings, Inc. develops, manufactures, researches, and distributes plant-based health products, including nutraceuticals, cannabinoids, functional mushrooms, and kratom. The company operates through business segments that provide branded natural remedies under lines such as PANA Health, PANA Beauty, and PANA Sport, along with white-label licensing and contract manufacturing of softgels for external businesses. Additionally, it sells botanical beverages, teas, and alternative wellness items through corporate-owned retail locations and distribution operations. Its customer base includes individual consumers reached via e-commerce and retail storefronts, as well as healthcare providers, dispensaries, and business clients.

Company profile, executives and history

Panacea Life Sciences stock: common questions

What is Panacea Life Sciences's stock price?

PLSH closed at $0.07 on Oct 19, 2026, up 5.45% on the day.

What is Panacea Life Sciences's market cap?

Panacea Life Sciences was worth $1.15M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is PLSH's P/E ratio?

Panacea Life Sciences lost money over the twelve months to Mar 31, 2024 (diluted EPS -$0.46), so it has no meaningful P/E ratio.

How much revenue does Panacea Life Sciences make?

Panacea Life Sciences reported revenue of $2.76M for the twelve months to Mar 31, 2024, up 50.4% from a year earlier.

Does Panacea Life Sciences pay a dividend?

No. Panacea Life Sciences has not paid a cash dividend over the last twelve months.

How has PLSH stock performed over the past year?

Including dividends, PLSH returned -0.6% over the past year, against +16.6% for the S&P 500.

Who are Panacea Life Sciences's competitors?

Companies most similar to Panacea Life Sciences by business, industry and size include NTRR, CYAN, FTLF, HYEX, NAII.

See a number that looks wrong?